SABCS 2018 Adjuvant capecitabine did not significantly improve outcomes for patients with earlystage triplenegative breast cancer

SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple-negative breast cancer

11:45 EST 7 Dec 2018 | ecancermedicalscience

Treating patients who had early-stage triple-negative breast cancer with the chemotherapy agent capecitabine after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation,...

More From BioPortfolio on "SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple-negative breast cancer"